Outline Director's Room Experimental Chemotherapy Molecular Phamacology Molecular Biotherapy Genome Research Clinical Research Anticancer Drug Information Office (ADIO) Genatherapy

To the homepage of part management Our laboratory was established in January 2000, and our mission is to develop the methodology of anticancer drug screening and to study molecular pharmacology of anticancer drugs by adopting post-genomic techniques. Our research is focused on two challenges directed to developing more effective personalized cancer chemotherapy, i.e. discovery of new anticancer compounds and identification of genes and proteins that predict or determine the chemosensitivity of cancer cells. We are studying a panel of 39 human cancer cell lines (JFCR39) that originated from various types of cancer. First, we established a chemosensitivity database in JFCR39, which enabled us to develop an effective 'wet and dry' system to screen anticancer compounds having unique mechanisms of action. Next, we examined gene expression profiles in JFR39 and developed a gene expression database. Furthermore, we have recently established another database of protein expression profiles in JFCR39 by using Western blot analysis and SELDI protein chip system, and integrated these three databases. Now we are trying to identify genes and proteins that relate with chemosensitivity using bioinformatics. (1) Drug discovery and evaluation (2) Identification of genes related with chemosensitivity (3) Identification of biomarkers of tumor diagnosis Institute Deputy Director· Chief Takao Yamori Staff Scientist Shingo Dan Postdoctoral Scientist Dexin Kong Visiting fellow Shinichi Yaguchi, Hisashi Yoshimi, Sho Isoyama Visiting Ph.D. Student Misa Niitsu, Yuta Yamazaki, Naoki Nakamura Visiting Student Gensei Kajiwara Technical Assistant Yoshimi Ohashi, Kanami Yamazaki, Yumiko Nishimura, Mutsumi Okamura, Mariko Seki, Yumiko Mukai, Naomi Tamaki Management assistant Yurina Anzai